These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 18317246)
1. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246 [TBL] [Abstract][Full Text] [Related]
2. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339 [TBL] [Abstract][Full Text] [Related]
4. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558 [TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages. Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
7. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948 [TBL] [Abstract][Full Text] [Related]
8. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779 [TBL] [Abstract][Full Text] [Related]
11. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Engelborghs S; De Vreese K; Van de Casteele T; Vanderstichele H; Van Everbroeck B; Cras P; Martin JJ; Vanmechelen E; De Deyn PP Neurobiol Aging; 2008 Aug; 29(8):1143-59. PubMed ID: 17428581 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. Formichi P; Battisti C; Radi E; Federico A J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254 [TBL] [Abstract][Full Text] [Related]
15. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996 [TBL] [Abstract][Full Text] [Related]
16. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Maddalena A; Papassotiropoulos A; Müller-Tillmanns B; Jung HH; Hegi T; Nitsch RM; Hock C Arch Neurol; 2003 Sep; 60(9):1202-6. PubMed ID: 12975284 [TBL] [Abstract][Full Text] [Related]